SANA Stock Analysis: Buy, Sell, or Hold?
SANA - Sana Biotechnology, Inc. Common Stock
$3.91
0.17 (4.55%)
▲
5d:
+10.14%
30d:
+21.81%
90d:
+24.13%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When SANA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SANA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SANA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: SANA is currently trading at $3.91, which is considered extended relative to its 30-day fair value range of $3.18 to $3.71.
Technical Outlook: Technically, SANA is in a uptrend. Immediate support is located at $3.37, while resistance sits at $4.12. The stock is showing strong short-term momentum, up 4.5% recently.
Market Sentiment: SANA scores 3/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.43 (+125.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SANA is in a uptrend. Immediate support is located at $3.37, while resistance sits at $4.12. The stock is showing strong short-term momentum, up 4.5% recently.
Market Sentiment: SANA scores 3/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.43 (+125.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.18 -
$3.71
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range (+5.4% above its trading range)
- BEARISH: Weak technical setup (3/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.5%)
- BULLISH: Trading 125.4% below Wall St target ($8.43)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.18 -
$3.71
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.37
Resistance Level
$4.12
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.74
Wall Street Target
$8.43
(+125.4%)
Share & Embed Analysis
Last updated: August 23, 2026 8:21 PM ET
Data refreshes hourly during market hours. Next update: 9:21 PM
Data refreshes hourly during market hours. Next update: 9:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SANA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1173 | 43 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
